MX2016013680A - Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. - Google Patents
Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.Info
- Publication number
- MX2016013680A MX2016013680A MX2016013680A MX2016013680A MX2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lipid storage
- storage disorders
- compositions
- treatment
- Prior art date
Links
- 230000013190 lipid storage Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000012190 activator Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000014060 Niemann-Pick disease Diseases 0.000 abstract 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 abstract 1
- 229960005520 bryostatin Drugs 0.000 abstract 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 abstract 1
- 229960005539 bryostatin 1 Drugs 0.000 abstract 1
- MJQUEDHRCUIRLF-YCVQJEHTSA-N bryostatins Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)C([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-YCVQJEHTSA-N 0.000 abstract 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
Tratamiento de sujetos que tienen un trastorno por el almacenamiento de lípidos con una composición que comprende un activador de PKC, tal como briostatinas, briólogos y ácidos grasos pollinsaturados; por consiguiente, la presente descripción provee métodos para tratar a sujetos humanos que sufren de trastornos por el almacenamiento de lípidos, tal como la enfermedad de Niemann-Pick, administrando activadores de PKC; la presente descripción provee, de conformidad con ciertas modalidades, métodos que comprenden administrar a un sujeto con enfermedad de Niemann-Pick Tipo C, una cantidad farmacéuticamente efectiva de briostatina 1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461981473P | 2014-04-18 | 2014-04-18 | |
| US201461987360P | 2014-05-01 | 2014-05-01 | |
| PCT/US2015/025821 WO2015160851A1 (en) | 2014-04-18 | 2015-04-14 | Methods and compositions for treatment of lipid storage disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016013680A true MX2016013680A (es) | 2017-07-05 |
Family
ID=54321042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013680A MX2016013680A (es) | 2014-04-18 | 2015-04-14 | Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9724328B2 (es) |
| EP (1) | EP3131543A4 (es) |
| JP (1) | JP2017511387A (es) |
| KR (1) | KR20170031653A (es) |
| CN (1) | CN107072982A (es) |
| CA (1) | CA2946115A1 (es) |
| IL (1) | IL248494A0 (es) |
| MX (1) | MX2016013680A (es) |
| WO (1) | WO2015160851A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018034318A1 (ja) | 2016-08-18 | 2018-02-22 | 国立大学法人 奈良先端科学技術大学院大学 | 免疫調節剤 |
| WO2019204582A1 (en) * | 2018-04-20 | 2019-10-24 | Retrotope, Inc. | Stabilized polyunsaturated compounds and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7256286B2 (en) | 1999-11-30 | 2007-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| WO2001040214A1 (en) | 1999-11-30 | 2001-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| CA2490494A1 (en) | 2002-07-02 | 2004-01-15 | Blanchette Rockefeller Neurosciences Institute | Pkc activation as a means for enhancing sapp.alpha. secretion and improving cognition using bryostatin type compounds |
| US8497385B2 (en) | 2007-08-31 | 2013-07-30 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| WO2009099563A2 (en) * | 2008-02-05 | 2009-08-13 | Blanchette Rockefeller Neurosciences Institute | Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease |
| JP5653917B2 (ja) | 2008-07-28 | 2015-01-14 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| WO2011019763A2 (en) * | 2009-08-10 | 2011-02-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for the treatment of krabbe and other neurodegenerative diseases |
| EP2776018B1 (en) * | 2011-11-13 | 2021-08-25 | Cognitive Research Enterprises, Inc. | Pkc activators and combinations thereof |
| WO2015148975A1 (en) * | 2014-03-27 | 2015-10-01 | Alkon Daniel L | Compositions and methods to treat niemann-pick disease |
-
2015
- 2015-04-14 MX MX2016013680A patent/MX2016013680A/es unknown
- 2015-04-14 JP JP2017506619A patent/JP2017511387A/ja active Pending
- 2015-04-14 WO PCT/US2015/025821 patent/WO2015160851A1/en not_active Ceased
- 2015-04-14 EP EP15780368.5A patent/EP3131543A4/en not_active Withdrawn
- 2015-04-14 CA CA2946115A patent/CA2946115A1/en not_active Abandoned
- 2015-04-14 CN CN201580032762.2A patent/CN107072982A/zh active Pending
- 2015-04-14 US US14/686,711 patent/US9724328B2/en not_active Expired - Fee Related
- 2015-04-14 US US15/304,838 patent/US20170172978A1/en not_active Abandoned
- 2015-04-14 KR KR1020167032127A patent/KR20170031653A/ko not_active Withdrawn
-
2016
- 2016-10-25 IL IL248494A patent/IL248494A0/en unknown
-
2019
- 2019-01-15 US US16/247,880 patent/US20190201377A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN107072982A (zh) | 2017-08-18 |
| EP3131543A1 (en) | 2017-02-22 |
| IL248494A0 (en) | 2016-12-29 |
| US20170172978A1 (en) | 2017-06-22 |
| US9724328B2 (en) | 2017-08-08 |
| US20150297559A1 (en) | 2015-10-22 |
| US20190201377A1 (en) | 2019-07-04 |
| EP3131543A4 (en) | 2017-12-20 |
| JP2017511387A (ja) | 2017-04-20 |
| WO2015160851A1 (en) | 2015-10-22 |
| KR20170031653A (ko) | 2017-03-21 |
| CA2946115A1 (en) | 2015-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| GB201318761D0 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
| WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
| WO2014004861A3 (en) | Methods of treating pediatric metabolic syndrome | |
| BR112015022197A2 (pt) | tratamento de cataplexia | |
| EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
| MX394764B (es) | Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina | |
| SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
| EA201490512A1 (ru) | Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека | |
| MX362185B (es) | Composiciones y tratamiento para enfermedades y trastornos del ojo. | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| EA201692292A1 (ru) | Соединения и композиции для стимулирования хондрогенеза | |
| MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| WO2015023691A3 (en) | 4-methylumbelliferone treatment for immune modulation | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| MX2023005014A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
| PH12016501159A1 (en) | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system | |
| MX2016013680A (es) | Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. | |
| BR112013026644A2 (pt) | método para a modulação da atividade de citocina | |
| BR112015007095A2 (pt) | derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados | |
| MX2018013324A (es) | Métodos y composiciones para el tratamiento del síndrome de rett. |